Clifford Swan Investment Counsel LLC Sells 170 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Clifford Swan Investment Counsel LLC trimmed its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 13.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,050 shares of the medical equipment provider’s stock after selling 170 shares during the period. Clifford Swan Investment Counsel LLC’s holdings in Intuitive Surgical were worth $354,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. OFI Invest Asset Management acquired a new position in shares of Intuitive Surgical during the third quarter worth approximately $25,000. Baystate Wealth Management LLC raised its stake in Intuitive Surgical by 150.0% during the 4th quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 45 shares during the last quarter. MCF Advisors LLC grew its position in Intuitive Surgical by 108.1% in the 4th quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 40 shares during the last quarter. Headinvest LLC bought a new position in shares of Intuitive Surgical during the 3rd quarter worth about $28,000. Finally, Stone House Investment Management LLC raised its position in shares of Intuitive Surgical by 100.0% during the third quarter. Stone House Investment Management LLC now owns 100 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 50 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insider Buying and Selling at Intuitive Surgical

In related news, VP Marshall Mohr sold 108,790 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the transaction, the vice president now directly owns 26,877 shares of the company’s stock, valued at approximately $10,349,795.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Intuitive Surgical news, President David J. Rosa sold 80,710 shares of the company’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $389.28, for a total value of $31,418,788.80. Following the transaction, the president now directly owns 163,399 shares of the company’s stock, valued at approximately $63,607,962.72. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Marshall Mohr sold 108,790 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the completion of the sale, the vice president now directly owns 26,877 shares of the company’s stock, valued at approximately $10,349,795.16. The disclosure for this sale can be found here. Insiders have sold 228,637 shares of company stock worth $88,483,248 over the last 90 days. Company insiders own 0.80% of the company’s stock.

Intuitive Surgical Trading Up 0.4 %

Shares of NASDAQ:ISRG traded up $1.69 during trading on Monday, hitting $383.05. 878,104 shares of the company were exchanged, compared to its average volume of 1,616,046. The stock has a market cap of $135.87 billion, a price-to-earnings ratio of 68.84, a P/E/G ratio of 4.93 and a beta of 1.39. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $403.76. The firm has a fifty day moving average price of $385.40 and a two-hundred day moving average price of $350.34.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. The business had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same period in the previous year, the company earned $1.00 earnings per share. As a group, research analysts predict that Intuitive Surgical, Inc. will post 4.8 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on ISRG. Royal Bank of Canada raised their price objective on Intuitive Surgical from $400.00 to $432.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 24th. Robert W. Baird reduced their price objective on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a report on Friday, April 19th. Jefferies Financial Group upped their target price on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research note on Friday, April 19th. Citigroup raised their price target on shares of Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Finally, Raymond James increased their target price on Intuitive Surgical from $372.00 to $435.00 and gave the stock an “outperform” rating in a report on Thursday, January 25th. Five research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $396.17.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.